Jun 16, 2003|
Ranbaxy: Generics Powering Growth
Indian pharma majors have been preparing for the post 2005 regime for some time now. One of the most aggressive among them is Ranbaxy, India’s largest pharmaceutical company. Traditionally, Ranbaxy has been a therapeutic segment oriented company. However, it is among the first to take a lead in pharma R&D in the country. In this article, we shall analyse the business structure of the company and its growth prospects.
Ranbaxy is primarily into export of generics. In 2002, generics constituted 86% of Ranbaxy’s total revenues up from 76% if 2001. The remaining 14% was accounted for by the API (bulk drugs) sales and allied activities. This is a healthy shift as the margins in generics sales are higher as compared to APIs.
Therapeutic distribution of global generics sales (%)
(Source: Ranbaxy Annual Reports)
|Central Nervous System (CNS)
|Gastro Intestinal Tract
As can be seen from the table, in therapeutics, anti-infectives still dominate Ranbaxy’s portfolio. Ranbaxy’s Cephalosporin range of brands contributed to 31% of the company’s global anti-infectives sales. The company has, however, started gradually increasing its focus on lifestyle segments like cardiovasculars and CNS. Cardiovasculars generated revenues to the tune of US$ 42.7 m in 2002, while the CNS segment notched up revenues of US$ 28.4 m. The global CNS market was at US$ 52 bn in 2001, and is expected to be around US$ 77 bn by 2007, representing a CAGR growth of 6.8%. Ranbaxy, as a result, stands to gain in the future.
Apart from Ranbaxy’s entry into high value lifestyle segments, exports have also played a bigger role in its growth (70% of revenues). USA is emerging as the major export market for the company with revenues to the tune of US$ 296 m (39% of sales). Ranbaxy has been ranked the second fastest growing generics company in USA. In Brazil, Ranbaxy has achieved sales of US$ 32 m in its second year of operation and has launched 19 new products (15% market share in the generic market in Brazil). Europe too saw strong growth and recorded sales of US$ 30 m. In China, however, massive price cuts announced by the State Drug Pricing Company has resulted in Ranbaxy suffering losses in FY02.
|R & D (% of Revenues)
Apart from generics, R&D has emerged as the other thrust area. The company’s R & D expenditure has increased from 2.8% of revenues in 1999 to 5.6% in 2002. It has made 115 patent applications in 2002 as against 46 in 1999.
Ranbaxy’s NCE Pipeline
||Stage of Development
||IND Filed /
|Urology - BPH
||RBx 6198, RBx 9001
||RBx 2258 (UK)
||RBx 2258 (India)
|Anti - Bacterial
Read more on pharma R&D
It is estimated that the global generics market will grow at the rate of 10% to 12%, with drugs having estimated sales of US$ 55 bn to 65 bn going off patent in the next five years. This indicates huge growth potential for Ranbaxy, as it will be able to capture a reasonable share of this market. Also, with pressure to reduce the health care costs in USA, the US government will be under pressure to speed up the generics approval procedure, thereby further helping Ranbaxy’s growth.
However, there are some caveats.
- Since Ranbaxy is required to comply with strict regulatory requirements, legal expenses are bound to rise.
- Currently, the key revenue driver is the therapeutic segment. Recently, it has started showing stagnant growth rates, which is a cause of concern.
- With the company now undertaking research in new drug discovery, the risk of the NCE failing in any of the clinical stages is very high and could result in the loss of huge R & D expenditure.
The stock currently trades at Rs 723 implying a P/E multiple of 19.3x annualised 1QFY04 earnings. Ranbaxy has a strong NCE pipeline. It’s Urology–BPH molecule RBx 2258 is currently undergoing Phase 2 Clinical Trials in India and Phase 1 Trials in UK (Licensed to Schwarz Pharma). Besides, it has 4 molecules in the early discovery stage. Ranbaxy has filed 25 ANDAs in 2002 as against 10 in 2000.
Considering Ranbaxy’s strong growth potential in the generics segment combined with the strong NCE pipeline and ANDAs, one is optimistic over the long-term. However, the risk profile of the stock is also on the higher end given the inherent risks involved in NCEs and complex regulatory procedures on the ANDA front.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks